Diana Buist, PhD, MPH, is an epidemiologist and health services researcher with extensive experience conducting comparative effectiveness research. Her work focuses on reducing harms and increasing benefits for patients in the area of cancer screening and outcomes spanning across patient, provider, and system factors.
Dr. Buist has an extensive record of practical research that has led to many efforts to improve care, including the development and refinement of national breast cancer screening guidelines and their implementation within Kaiser Permanente Washington. She has been conducting research within Kaiser Permanente Washington for more than 20 years and is a strong believer in patient-centered care and the important role patients play in improving the value and quality of health care. Dr. Buist is involved in several studies aimed at providing high-value health care that provides patients and their providers with information on the expected benefits and harms of cancer screening and treatment strategies.
Dr. Buist also has a long history collaborating with external researchers, including helping lead two large national research consortia focused on improving cancer screening and outcomes: the National Cancer Institute’s Breast Cancer Surveillance Consortium and the Cancer Research Network of the Health Care Systems Research Network. Her extensive experience working with diverse data from these consortia in longitudinal studies and randomized trials in clinical systems puts Dr. Buist in a unique position to examine screening, care, and outcomes in health systems across the country.
As Kaiser Permanente Washington Health Research Institute (KPWHRI) Director of Research and Strategic Partnerships, Dr. Buist works with other Kaiser Permanente regions, our local academic partners, and other external collaborators to build enduring strategic partnerships to enhance KPWHRI’s mission, align with KPWHRI faculty research priorities, and capitalize on our unique strengths in ways that are consistent with our mission.
Dr. Buist contributes to a variety of other projects at KPWHRI, including:
Dr. Buist is also an affiliate professor in the Departments of Epidemiology and Health Services at the University of Washington School of Public Health and an affiliate member at Fred Hutchinson Cancer Research Center. She enjoys sharing her expertise by mentoring junior faculty and PhD and MPH candidates and teaching courses.
Cancer screening and prevention; outreach and primary care prevention; comparative effectiveness; cost transparency; surveillance; secondary prevention; breast cancer treatment; breast cancer screening; outcomes following cancer diagnosis; cancer survivorship; provider variability in care
Cancer prevention and control; quality of care; preventive care; high-value care; consumer engagement in preventive medicine; systematic reviews
Cancer prevention and control
Trabert B, Bauer DC, Buist DSM, Cauley JA, Falk RT, Geczik AM, Gierach GL, Hada M, Hue TF, Lacey JV Jr, LaCroix AZ, Tice JA, Xu X, Dallal CM, Brinton LA. Association of circulating progesterone with breast cancer risk among postmenopausal women. JAMA Netw Open. 2020 Apr 1;3(4):e203645. doi: 10.1001/jamanetworkopen.2020.3645. PubMed
Schaffter T, Buist DSM, Lee CI, Nikulin Y, Ribli D, Guan Y, Lotter W, Jie Z, Du H, Wang S, Feng J, Feng M, Kim HE, Albiol F, Albiol A, Morrell S, Wojna Z, Ahsen ME, Asif U, Jimeno Yepes A, Yohanandan S, Rabinovici-Cohen S, Yi D, Hoff B, Yu T, Chaibub Neto E, Rubin DL, Lindholm P, Margolies LR, McBride RB, Rothstein JH, Sieh W, Ben-Ari R, Harrer S, Trister A, Friend S, Norman T, Sahiner B, Strand F, Guinney J, Stolovitzky G; and the DM DREAM Consortium, Mackey L, Cahoon J, Shen L, Sohn JH, Trivedi H, Shen Y, Buturovic L, Pereira JC, Cardoso JS, Castro E, Kalleberg KT, Pelka O, Nedjar I, Geras KJ, Nensa F, Goan E, Koitka S, Caballero L, Cox DD, Krishnaswamy P, Pandey G, Friedrich CM, Perrin D, Fookes C, Shi B, Cardoso Negrie G, Kawczynski M, Cho K, Khoo CS, Lo JY, Sorensen AG, Jung H. Evaluation of combined artificial intelligence and radiologist assessment to interpret screening mammograms. JAMA Netw Open. 2020 Mar 2;3(3):e200265. doi: 10.1001/jamanetworkopen.2020.0265. PubMed
Malone C, Barnabas RV, Buist DSM, Tiro JA, Winer RL. Cost-effectiveness studies of HPV self-sampling: a systematic review. Prev Med. 2020 Jan 3:105953. doi: 10.1016/j.ypmed.2019.105953. [Epub ahead of print]. PubMed
Schifferdecker KE, Tosteson ANA, Kaplan C, Kerlikowske K, Buist DSM, Henderson LM, Johnson D, Jaworski J, Jackson-Nefertiti G, Ehrlich K, Marsh MW, Vu L, Onega T, Wernli KJ. Knowledge and perception of breast density, screening mammography, and supplemental screening: in search of "informed". J Gen Intern Med. 2019 Dec 2. pii: 10.1007/s11606-019-05560-z. doi: 10.1007/s11606-019-05560-z. [Epub ahead of print]. PubMed
Malone C, Tiro JA, Buist DS, Beatty T, Lin J, Kimbel K, Gao H, Thayer C, Miglioretti DL, Winer RL. Reactions of women underscreened for cervical cancer who received unsolicited human papillomavirus self-sampling kits. J Med Screen. 2019 Nov 20:969141319885994. doi: 10.1177/0969141319885994. [Epub ahead of print]. PubMed
Eavey J, Ramaprasan A, Abraham L, Buist DS. Comorbidity index score increases due to coding artifacts. Epidemiology. 2019 Nov 20. doi: 10.1097/EDE.0000000000001142. [Epub ahead of print]. PubMed
Winer RL, Lin J, Tiro JA, Miglioretti DL, Beatty T, Gao H, Kimbel K, Thayer C, Buist DSM. Effect of mailed human papillomavirus test kits vs usual care reminders on cervical cancer screening uptake, precancer detection, and treatment: a randomized clinical trial. JAMA Netw Open. 2019;2(11):e1914729. Epub 2019/11/07. doi: 10.1001/jamanetworkopen.2019.14729. PubMed
Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, Eccles D, Hopper J, Li S, Southey M, Duffy S, Cuzick J, Dos Santos Silva I, Miners A, Sadique Z, Yang L, Legood R, Manchanda R. A cost-effectiveness analysis of multigene testing for all patients with breast cancer. JAMA Oncol. 2019 Oct. doi: 10.1001/jamaoncol.2019.3323. PubMed
Lee CI, Houssami N, Elmore JG, Buist DSM. Pathways to breast cancer screening artificial intelligence algorithm validation. Breast. 2019 Sep 9. pii: S0960-9776(19)30554-5. doi: 10.1016/j.breast.2019.09.005. [Epub ahead of print]. PubMed
Demb J, Abraham L, Miglioretti DL, Sprague BL, O'Meara ES, Advani S, Henderson LM, Onega T, Buist DSM, Schousboe JT, Walter LC, Kerlikowske K, Braithwaite D. Screening mammography outcomes: risk of breast cancer and mortality by comorbidity score and age. J Natl Cancer Inst. 2019 Sep 6. pii: 5556084. doi: 10.1093/jnci/djz172. [Epub ahead of print]. PubMed
The early-career scientists will receive 3 years of intensive training in Learning Health System research.
Admissions open for two new trainees as current scholars advance their projects.
Dr. Diana Buist and team reflect on HOME trial showing 50 percent screening boost in underscreened women.
Interdisciplinary group shows that home-based HPV tests can boost cervical cancer screening for women at high risk.
Kaiser Permanente Washington has been part of the national Breast Cancer Surveillance Consortium since 1994. Learn about the Kaiser Permanente Washington Breast Cancer Surveillance Registry here.
A Kaiser Permanente-led BCSC study is among the largest ever to evaluate adding MRI surveillance for breast cancer survivors.
HealthDay, Nov 8, 2019